Trastuzumab treatment of invasive breast ductal carcinoma induces severe edema: a case report

BACKGROUND: Trastuzumab, a monoclonal antibody which binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), is the first biological drug approved for the treatment of HER2-positive breast cancer. However, trastuzumab exhibits a series of clinical adverse effects, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hua, Zheng, Jie, Wang, Qin, Ai, Yueqin, Zhao, Ying, Wang, Jing, Qu, Shuang, Hu, Jianhua, Jia, Shaochang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745366/
https://www.ncbi.nlm.nih.gov/pubmed/36523319
http://dx.doi.org/10.21037/tcr-22-1607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745366/
https://www.ncbi.nlm.nih.gov/pubmed/36523319
http://dx.doi.org/10.21037/tcr-22-1607

Ejemplares similares